U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Compliance Actions (Biologics)
  1. Guidance, Compliance & Regulatory Information (Biologics)

CBER carries out a wide range of compliance and surveillance activities during the "life cycle" of biological products, including:

  • Conducting pre-license and pre-approval inspections of manufacturing facilities and products under clinical study.
  • Monitoring the safety, purity and potency of biological products through review of:
    • Biological Product Deviation Reports (BPDRs) and HCT/P Deviation Reports,
    • Investigations into transfusion and donation related fatalities and other adverse events,
    • Product recalls.
  • Monitoring reports of biological product shortages.
  • Initiating regulatory action to address non-compliance with FDA laws and regulations.
  • Monitoring of research conducted on biological products and assessing the protection of the rights, safety, and welfare of human research subjects and the quality and integrity of research data.
  • Monitoring import and export activities.
  • Reviewing product advertising and promotional labeling.

Adverse Events and Product Deviations

Recalls

Product Safety & Availability

Inspections

Regulatory Actions Issued by CBER

Administrative Actions Issued By CBER


Sub-Topic Paragraphs

Follow CBER

Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002

ocod@fda.hhs.gov

(800) 835-4709
(240) 402-8010

For Updates on Twitter, follow @fdacber


Subscribe for CBER Updates

Get e-mail updates on What’s New at CBER!

Back to Top